AAE方案联合环孢霉素A治疗难治性急性非淋巴细胞白血病  

Therapeutic effect of AAE plan plus cyclosporin A on refractory acute nonlymphoblastic leukemia

作　　者：胡明均[1] 李红[1] 鲍红霞[1] 刘瑜[2] 李爱华[1] 李玉玲[1] 

机构地区：[1]郧阳医学院附属人民医院血液内科,湖北十堰442000 [2]郧阳医学院附属太和医院血液内科

出　　处：《疑难病杂志》2007年第8期472-474,共3页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的探讨难治性急性非淋巴细胞白血病(ANLL)的有效治疗方法。方法22例难治性ANLL采用阿糖胞苷(Ara-C)、安吖啶(AMSA)和依托泊苷(VP16)组成的AAE方案联合反转耐药剂环孢霉素A(CsA)治疗,7d为1个疗程,疗程结束3周后评价疗效,并观察不良反应发生情况。结果22例患者中,完全缓解13例,完全缓解率为59.1%,部分缓解4例,部分缓解率为18.2%,总有效率77.3%。完全缓解的13例患者中,1个疗程缓解9例(69.2%),2个疗程缓解3例(23.1%),3个疗程缓解1例(7.7%)。22例中发生骨髓抑制12例(54.5%),合并严重感染7例(31.8%),口腔溃疡11例(50.0%)。结论AAE方案联合CsA治疗难治性ANLL有一定的效果。Objective To explore the therapeutic plan for refractory acute nonlymphoblastic leukemia （ANLL） .Methods 22 patients with refractory ANLL were treated with cyclosporin A （CsA） and AAE plan,which consisted ofCsA （CsA 8 mg·kg^-1 ·d^-1 ,dl - 3;4 mg·kg^-1 ·d^-1 ,d4 - 5,taken orally） ;Ara-C （200 rag/d, dl - 7,intravenous）, AMSA （75 rag/ d, dl - 3, intravenous）, VP16 （ 100 mg/d, dl - 4, intravenous）, with a treatment course of 7 days. 3 weeks after chemotherapy the therapeutic effect was evaluated, and the side effects were observed. Results Complete remission rate was 59.1%, partial remission rate was 18.2%, total effective rate was 77.3%. Among 13 complete remission patients,9 cases （69.2%）were remitted within one treatment course;3 cases （23.1% ） were remitted within two treatment courses; 1 case （7.7%） were remitted within 3 treatment courses. Among 22 patients, 12 cases （54.5%） had arrest of bone marrow;7 cases （31.8%）had severe infection; 11 cases（50.0% ） had ulcerative stomatitis. Conclusion AAE Plus CsA plan is effective in the treatment of refractory ANLL.

关 键 词：白血病 非淋巴细胞性 AAE方案 环孢霉素A 

分 类 号：R733.7[医药卫生—肿瘤]